Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NSE4

UPID:
SYIM_HUMAN

ALTERNATIVE NAMES:
Isoleucyl-tRNA synthetase

ALTERNATIVE UPACC:
Q9NSE4; B2RPG8; Q1M2P9; Q6PI85; Q7L439; Q86WU9; Q96D91; Q9H9Q8; Q9NW42

BACKGROUND:
Isoleucine--tRNA ligase, mitochondrial, known alternatively as Isoleucyl-tRNA synthetase, is essential for mitochondrial protein synthesis. It ensures the proper addition of isoleucine to tRNA, a critical step in the translation of mRNA into proteins.

THERAPEUTIC SIGNIFICANCE:
Linked to a rare autosomal recessive disorder characterized by a spectrum of symptoms including cataracts and growth hormone deficiency, the study of Isoleucine--tRNA ligase, mitochondrial offers promising avenues for therapeutic intervention and disease understanding.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.